EMEA-000828-PIP01-09-M09
Key facts
| Invented name |
Jardiance
|
| Active substance |
empagliflozin
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0283/2021
|
| PIP number |
EMEA-000828-PIP01-09-M09
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000828-PIP01-09-M09
|
| Compliance opinion date |
16/12/2022
|
| Compliance outcome |
positive
|